Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- January 1993 (Revised April 1993)
- Case
Chadwick, Inc.: The Balanced Scorecard
By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
Keywords: Balanced Scorecard; Performance Evaluation; Customer Relationship Management; Goals and Objectives; Customer Satisfaction; Research and Development; Marketplace Matching; Financial Condition; Product Launch; Pharmaceutical Industry
Kaplan, Robert S. "Chadwick, Inc.: The Balanced Scorecard." Harvard Business School Case 193-091, January 1993. (Revised April 1993.)
- April 18, 2022
- Article
Will mRNA Technology Companies Spawn Innovation Ecosystems?
By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
The mRNA technologies that helped rapidly create effective COVID-19 vaccines could become technology platform businesses, which has tremendous implications for players in the world of drug development. These platforms could attract other companies interested in... View Details
Keywords: Health Care; Digital Health; Technology; Innovation; Health Care and Treatment; Technological Innovation; Digital Transformation; Health Industry; United States
Grimpe, Christoph, Timo Minssen, W. Nicholson Price, II, and Ariel Dora Stern. "Will mRNA Technology Companies Spawn Innovation Ecosystems?" Harvard Business Review (website) (April 18, 2022).
- February 2007 (Revised April 2010)
- Case
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
By: Robert S. Huckman, Gary P. Pisano and Mark Rennella
Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression... View Details
Keywords: Decision Making; Measurement and Metrics; Business Processes; Organizational Structure; Research and Development; Science-Based Business; Creativity; Pharmaceutical Industry
Huckman, Robert S., Gary P. Pisano, and Mark Rennella. "Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics." Harvard Business School Case 607-008, February 2007. (Revised April 2010.)
- 03 May 2022
- News
Q&A With Harvard Business School Professor Linda A. Hill
- August 2008 (Revised September 2008)
- Supplement
The Flaxil Label (C): Debrief and Endnotes
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details
Keywords: Safety; Value Creation; Negotiation; Health Care and Treatment; Sales; Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (C): Debrief and Endnotes." Harvard Business School Supplement 909-003, August 2008. (Revised September 2008.)
- October 2011 (Revised June 2013)
- Case
Novo Nordisk: A Commitment to Sustainability
By: Robert G. Eccles and Michael P. Krzus
The case describes the early commitment of a European pharmaceutical company, Novo Nordisk, to integrated reporting. Novo Nordisk is one of the pioneers of integrated reporting and it emerged out of its commitment to a "Triple Bottom Line approach to managing the... View Details
Keywords: Strategic Planning; Business Ventures; Business or Company Management; Integrated Corporate Reporting; Business Strategy; Pharmaceutical Industry
Eccles, Robert G., and Michael P. Krzus. "Novo Nordisk: A Commitment to Sustainability." Harvard Business School Case 412-053, October 2011. (Revised June 2013.)
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (B)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details
Keywords: Governance; Risk and Uncertainty; Value Creation; Negotiation; Attitudes; Health Care and Treatment; Government Administration; Pharmaceutical Industry; United States
Barron, Greg M. "The Flaxil Label (B)." Harvard Business School Case 909-002, August 2008. (Revised September 2008.)
- September 2013 (Revised February 2016)
- Case
GlaxoSmithKline: Sourcing Complex Professional Services
By: Heidi K. Gardner and Silvia Hodges Silverstein
Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional time-based billing with data-driven decision making and an online reverse auction. In... View Details
Keywords: Legal Industry; Procurement; Professional Service Firms; Pricing; Competition; Change Management; Supply Chain Management; Legal Liability; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry
Gardner, Heidi K., and Silvia Hodges Silverstein. "GlaxoSmithKline: Sourcing Complex Professional Services." Harvard Business School Case 414-003, September 2013. (Revised February 2016.)
- February 2010
- Case
Real Blue? Viagra and Intellectual Property Rights Law in China
By: Regina M. Abrami and Tracy Manty
On July 5, 2004, Pfizer's China team received disappointing news. China's patent review board just invalidated the company's existing patent on one of its most successful drugs, Viagra. Making matters worse, a Guangdong-based pharmaceutical company laid claim to... View Details
Keywords: Trade; International Relations; Patents; Trademarks; Lawsuits and Litigation; Rights; Business and Government Relations; Pharmaceutical Industry; China
Abrami, Regina M., and Tracy Manty. "Real Blue? Viagra and Intellectual Property Rights Law in China." Harvard Business School Case 910-409, February 2010.
- August 2001
- Case
Finnigan Corporation
By: Carliss Y. Baldwin and Barbara Feinberg
Finnigan Corp., headquartered in San Jose, CA, was the world's leading producer of mass spectrometers, holding a 45% market share of instruments used for chemical analysis in pharmaceutical product development, environmental testing, genetic testing, and other... View Details
Keywords: Business Exit or Shutdown; Financial Crisis; Machinery and Machining; Technology Industry; San Jose
Baldwin, Carliss Y., and Barbara Feinberg. "Finnigan Corporation." Harvard Business School Case 902-045, August 2001.
- September 1991 (Revised February 1993)
- Case
Burroughs Wellcome and AZT (A)
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details
Keywords: Governing Rules, Regulations, and Reforms; Ethics; Business and Government Relations; Communication Strategy; Health Care and Treatment; Monopoly; Intellectual Property; Research and Development; Price; Pharmaceutical Industry; London
Emmons, Willis M., III. "Burroughs Wellcome and AZT (A)." Harvard Business School Case 792-004, September 1991. (Revised February 1993.)
- May 2014
- Article
Right Up the Middle: How Israeli Firms Go Global
By: Jonathan Friedrich, Amit Noam and Elie Ofek
The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details
Friedrich, Jonathan, Amit Noam, and Elie Ofek. "Right Up the Middle: How Israeli Firms Go Global." Harvard Business Review 92, no. 5 (May 2014): 113–117.
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (A)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Product Launch; Negotiation Process; Business and Government Relations; Safety; Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (A)." Harvard Business School Case 909-001, August 2008. (Revised September 2008.)
- 09 Jun 2015
- News
How Merck Is Trying to Keep Disrupters at Bay
- October 2023 (Revised June 2024)
- Case
Catalent: Catalyzing the Next Era of Growth
By: Satish Tadikonda, William Marks and Kevin Emancipator
Catalent's newly appointed CEO, Alessandro Maselli, experienced the highs of the pharmaceutical contract development manufacturing (CDMO) space during COVID-19 while helping Moderna and others bring vaccines to market quickly and safely. After rushing to add capacity... View Details
Keywords: Leadership; Business or Company Management; Organizational Change and Adaptation; Pharmaceutical Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Catalent: Catalyzing the Next Era of Growth." Harvard Business School Case 824-016, October 2023. (Revised June 2024.)
- 15 Jun 2021
- News
Podcast: How Biosimilars Are Affecting the Drug Markets
- 27 Sep 2011
- First Look
First Look: September 27
specificity at the individual level. We discuss the implications of our results for the study of learning and experience as well as for the providers and consumers of outsourced services. Download the paper: http://www.hbs.edu/research/pdf/11-057.pdf U.S. Healthcare... View Details
Keywords: Sean Silverthorne
- 06 Feb 2018
- News
What Could Amazon’s Approach to Health Care Look Like?
- April 1998 (Revised September 1998)
- Case
Jan Eriksson at Novartis Indonesia (A)
By: Carin-Isabel Knoop and Anthony St. George
Jan Eriksson is the country manager of the Novartis AG joint venture in Indonesia. At the time of the case, Novartis is the world's largest pharmaceutical company. The case describes the steps Eriksson took to merge the Indonesian operations of Novartis' parents,... View Details
Keywords: Multinational Firms and Management; Joint Ventures; Financial Crisis; Pharmaceutical Industry; Indonesia
Knoop, Carin-Isabel, and Anthony St. George. "Jan Eriksson at Novartis Indonesia (A)." Harvard Business School Case 898-219, April 1998. (Revised September 1998.)